CPXX News 2.80 Celator Pharma (CPXX)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 18, 2014 at 12:17 AM

Celator Pharma (CPXX) 2.80 $CPXX

Celator(R) Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.

Celator(R) Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2013.

Celator(R) Pharmaceuticals to Report Fourth Quarter and Year-End 2013 Financial Results on March 24, 2014
GlobeNewswire - Tue Mar 18, 3:01PM CDT
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, March 24, 2014 at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.

Celator(R) Pharmaceuticals Announces New Date and Time for Presentation at 16th Annual BIO CEO and Investor Conference
GlobeNewswire - Mon Feb 03, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will now present an overview of the company at the 16 Annual BIO CEO and Investor Conference on Monday, February 10, 2014, at 9:00 a.m. EST. The conference is being held at the Waldorf Astoria in New York.

Celator(R) Pharmaceuticals to Present at Upcoming Healthcare Conferences
GlobeNewswire - Tue Jan 14, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the company at two upcoming healthcare conferences.

Celator(R) Pharmaceuticals Reaches 50% Enrollment for CPX-351 Phase 3 Study
GlobeNewswire - Thu Jan 09, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has reached 50% of the study's planned enrollment of 300 patients.

Celator(R) Pharmaceuticals Approved for Approximately $1.5 Million From New Jersey's Technology Business Tax Certificate Transfer Program
GlobeNewswire - Tue Jan 07, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced today that the company has been approved for approximately $1.5 million, in non-dilutive financing, through New Jersey's Technology Business Tax Certificate Transfer Program.

Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
GlobeNewswire - Thu Dec 19, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of Joseph M. Lobacki to its Board of Directors.

Celator(R) Pharmaceuticals Announces Positive Data and Safety Monitoring Board Recommendation for CPX-351 Phase 3 Study
GlobeNewswire - Thu Dec 12, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3 ) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) should continue as planned without any modifications.

Celator(R) Pharmaceuticals to Present at Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Fri Dec 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, chief executive officer, will present an overview of the Company at the upcoming Oppenheimer 24 Annual Healthcare Conference.

Celator(R) Pharmaceuticals Announces Business Update and Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:00PM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported third quarter 2013 financial results.

Celator(R) Pharmaceuticals Announces Appointment of Les Mintzmyer as Vice-President Manufacturing and Technical Operations
GlobeNewswire - Tue Nov 12, 6:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the appointment of industry veteran Les Mintzmyer as vice-president, manufacturing and technical operations. Mintzmyer will be responsible for optimizing the Company's production, supply chain logistics, customer service, quality, and regulatory compliance, while working closely with the Company's contract supply and manufacturing organizations in the planning and introduction of new products.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Florida Cancer Center Expands Expertise with New Oncologist

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

Tenet® Beef: Revolutionizing Tenderness in America's Steaks

Cracking the Code: A Genetic Leap in Beef Tenderness Well, buckle up, folks, because Callipyge Genetics is shaking things up in the beef aisle with their genomic breakthrough, Tenet®. It's about time we see some real innovation in an industry that's, let's face it, been slow to evolve. This isn't just a flash in the pan—a bit of DNA parsing has uncovered how to...

Navigating the Nitty-Gritty of Cabin Rental Management

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Cancer Memoir Shows Healing Beyond Medicine

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

Firmable's Tech Intelligence: New Edge in B2B Sales

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

Endava Faces Securities Fraud Lawsuit: Investor Implications

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...